Oxford BioDynamics Plc (LSE:OBD) released its preliminary results for the year ended September 2025, reporting strong growth in orders for its EpiSwitch® Prostate Screening Test. The company also completed a £7 million fundraising during the period, strengthening its balance sheet and providing additional resources to support commercial expansion.
Strategically, the year was marked by several important developments. Oxford BioDynamics entered into a partnership with Google Cloud, enhancing its data and analytics capabilities, while continuing discussions with potential third-party partners aimed at broadening the application and distribution of its technology. These initiatives are intended to accelerate growth and create longer-term value for shareholders.
Despite these positive operational milestones, the company continues to face financial headwinds. Ongoing losses and negative cash flows remain a concern, and technical indicators point to bearish momentum in the shares. In addition, valuation metrics are pressured by the absence of earnings, resulting in a negative price-to-earnings ratio.
Taken together, Oxford BioDynamics offers exposure to innovative diagnostic technology and growing commercial traction, but this comes alongside elevated financial and execution risk.
More about Oxford BioDynamics
Oxford BioDynamics Plc is a precision clinical diagnostics company that develops highly specific and sensitive tests using its proprietary EpiSwitch® 3D genomics platform. The group focuses on clinical applications in areas such as cancer and chronic fatigue syndrome, with operations and commercial activity spanning the UK and the United States.
Leave a Reply